Recruiting

Study to Determine the Antitumor Activity of New CAR-macrophages in Breast Cancer Patients' Derived Organoids

Cell-based immune therapy using modified macrophages is a promising therapeutic approach in breast cancer. The objective of this cohort study is to collect tumor samples to develop patients' derived organoids to test the antitumor activity of newly developed CAR-macrophages. Other biological samples will be collected such as blood to analyze the host inflammatory status.

ClinicalTrials.gov IDNCT05007379

PhaseNot Applicable

Enrollment100

SponsorCentre Oscar Lambret

Age18 Years

SexALL

I'm interested View official listing

Conditions studied

Breast Cancer

About this study

Primary outcomes

Antitumor activity of the CAR-macrophages against organoids from HER2 negative, HER2 low and HER2 positive breast cancers (24 months)
Antitumor activity of the CAR-macrophages compared to non-modified macrophages (24 months)

Eligibility information

Inclusion Criteria: * Male or female aged 18 years or more * Histologically confirmed breast cancer at any stage * Requiring surgery or tumor biopsy as standard of care * Any or no systemic treatment * Signed informaed consent * Health insurance coverage Exclusion Criteria: * Opposed to biospecimen collection

Study locations

Oscar Lambret Center, Lille, 59000 France

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.